Novo Nordisk maintains 2026 outlook as FDA review of blood disorder drug extends

Novo Nordisk said it is maintaining its 2026 financial outlook, underscoring confidence in its long-term prospects. The statement came amid an extended review by the U.S. FDA of the company's blood disorder drug, which is taking longer than initially expected. Novo Nordisk noted that the approval timeline for the treatment remains uncertain, but stressed that its overall guidance has not changed. Market observers are watching the regulatory process closely, as any shift could influence the company's future earnings outlook. The firm added that it will continue to work with regulators and update stakeholders on any significant developments.